Editorial
Journal of hematology & oncology: A journal open to all
-
Correspondence: Delong Liu delong_liu@nymc.edu
Associate Professor of Medicine, New York Medical College, Munger Pavilion 250, Valhalla, NY 10595, USA
Journal of Hematology & Oncology 2008, 1:1 doi:10.1186/1756-8722-1-1
Published: 28 May 2008First paragraph (this article has no abstract)
Paul Ehrlich prophesied "magic bullet" in early 1900 [1], but it was not until 1975 that Kohler and Milstein developed the hybridoma technology [2]. Since then hematology and oncology have become closely intertwined and rapidly evolving fields. New findings from laboratory-based research are rapidly being turned into clinical applications. Within less than a decade, targeted therapy has become a treatment of choice for many diseases, with imatinib and rituximab representing the many recent major breakthroughs in cancer therapy [3,4].